Insider Selling: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Sells 31,897 Shares of Stock

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CEO Paula Ragan sold 31,897 shares of the business’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $0.56, for a total transaction of $17,862.32. Following the completion of the sale, the chief executive officer now owns 1,025,816 shares in the company, valued at $574,456.96. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Paula Ragan also recently made the following trade(s):

• On Monday, October 7th, Paula Ragan sold 239,436 shares of X4 Pharmaceuticals stock. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80.

X4 Pharmaceuticals Trading Down 4.3 %

Shares of NASDAQ:XFOR opened at $0.53 on Thursday. The company has a market capitalization of $89.51 million, a PE ratio of -0.76 and a beta of 0.36. The company has a current ratio of 6.07, a quick ratio of 6.04 and a debt-to-equity ratio of 0.79. X4 Pharmaceuticals, Inc. has a 12-month low of $0.47 and a 12-month high of $1.60. The business’s fifty day simple moving average is $0.66 and its 200-day simple moving average is $0.86.

X4 Pharmaceuticals (NASDAQ:XFOR) last announced its earnings results on Thursday, August 8th. The company reported ($0.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03). The business had revenue of $0.56 million for the quarter, compared to analyst estimates of $52.98 million. During the same period in the previous year, the company earned ($0.33) EPS. As a group, equities research analysts predict that X4 Pharmaceuticals, Inc. will post -0.65 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of X4 Pharmaceuticals in a report on Friday, June 28th.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in XFOR. K2 Principal Fund L.P. purchased a new stake in shares of X4 Pharmaceuticals during the second quarter valued at $284,000. AQR Capital Management LLC lifted its holdings in shares of X4 Pharmaceuticals by 1,080.3% during the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock worth $246,000 after purchasing an additional 388,115 shares during the period. Bank of New York Mellon Corp raised its position in X4 Pharmaceuticals by 39.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 469,372 shares of the company’s stock worth $272,000 after buying an additional 133,398 shares during the last quarter. XTX Topco Ltd purchased a new stake in shares of X4 Pharmaceuticals in the 2nd quarter valued at $65,000. Finally, Ensign Peak Advisors Inc lifted its position in X4 Pharmaceuticals by 4.6% during the second quarter. Ensign Peak Advisors Inc now owns 2,546,458 shares of the company’s stock valued at $1,477,000 after purchasing an additional 111,032 shares during the period. Hedge funds and other institutional investors own 72.03% of the company’s stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.